A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease.

Trial Profile

A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Interleukin-2; IPH 1101
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jul 2012 Official title amended and lead trial centre identified as reported by EudraCT.
    • 04 Jul 2012 Planned End Date 11 Apr 2009 added as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top